Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development
Search Refinements
Search Results: Drug Discovery & Development
1-15 of 5264 results
Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA
Onxeo announced its plan for further development of AsiDNA, its first-in-class signal interfering DNA molecule which breaks the cycle of tumor DNA repair to induce cancer cell death.
Drug Research > Drug Discovery & Development > News
Hengrui Therapeutics unveils $100m investment from HR Bio Holdings for global clinical development
Hengrui Therapeutics (HTI) has signed an agreement with HR Bio Holdings Limited, a joint venture between Jiangsu Hengrui Medicine Co. Ltd. (JHM) and an undisclosed blue chip investment firm, regarding a $100 million investment in HTI.
Drug Research > Drug Discovery & Development > News
Gene-editing firm CRISPR Therapeutics raises additional $38M in Series B Financing
By PBR Staff Writer
Gene-editing firm CRISPR Therapeutics has raised an additional $38m as part of series B financing, bringing the total investment in the round to about $140m.
Drug Research > Drug Discovery & Development > News
Pfizer acquires Anacor Pharmaceuticals for $5.2bn
By PBR Staff Writer
Pfizer has acquired Anacor Pharmaceuticals, which is engaged in the discovery, development and commercialization of novel small-molecule therapeutics, for $5.2bn.
Drug Research > Drug Discovery & Development > News
Yumanity Therapeutics and New York Stem Cell Foundation Research Institute form discovery collaboration
Yumanity Therapeutics announced a discovery collaboration with the New York Stem Cell Foundation (NYSCF) Research Institute, a non-profit organization dedicated to accelerating cures for major diseases through stem cell research.
Drug Research > Drug Discovery & Development > News
Compugen discloses lead therapeutic candidate for CGEN-15029 immuno-oncology program
Compugen disclosed at the JMP Securities Life Science Conference in NY, COM701 as the lead monoclonal antibody therapeutic candidate for the Company's CGEN-15029 target program.
Drug Research > Drug Discovery & Development > News
GW Pharmaceuticals selects infantile spasms for Epidiolex development program
GW Pharmaceuticals has selected infantile spasms (IS) as the fourth target indication for its Epidiolex orphan pediatric epilepsy development program.
Drug Research > Drug Discovery & Development > News
F2G raises $60m in funding to progress antifungal agents development
By PBR Staff Writer
UK-based antifungal drug discovery and development firm F2G has raised $60m in financing to progress development of novel antifungal agents.
Drug Research > Drug Discovery & Development > News
Blade Therapeutics raises $45m Series B Financing
Blade Therapeutics announced the closing of a Series B financing led by Deerfield Management, that will bring $45m into the company when all milestones are completed.
Drug Research > Drug Discovery & Development > News
Crown Bioscience strengthens global immuno-oncology platform
Crown Bioscience has strengthened its global Immuno-Oncology Platform at all its key facilities in Europe, US, and Asia to support client's needs with a comprehensive collection of validated models and services for in vivo pharmacodynamic and efficacy studies.
Drug Research > Drug Discovery & Development > News
Carbylan Therapeutics, KalVista Pharmaceuticals enter into share purchase agreement
Carbylan Therapeutics and KalVista Pharmaceuticals have entered into a definitive share purchase agreement pursuant to which the shareholders of KalVista will become the majority owners of Carbylan.
Drug Research > Drug Discovery & Development > News
Rgenix announces $33m series B financing to develop cancer therapeutics
Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33m Series B financing led by Novo A/S and Sofinnova Partners, with participation from existing investors including Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP.
Drug Research > Drug Discovery & Development > News
Biopharmaceutical firm Allecra Therapeutics raises EUR22m funding
By PBR Staff Writer
Biopharmaceutical firm Allecra Therapeutics has raised €22m in a series B investment round led by Delos Capital.
Drug Research > Drug Discovery & Development > News
Alpine Immune Sciences raises $48m to develop next generation immunotherapies
Alpine Immune Sciences (AIS), a privately held biotechnology company developing a next-generation immune system modulation platform, has closed its $48m Series A financing round.
Drug Research > Drug Discovery & Development > News
Spotlight Innovation finalizes plans to sign deal with Maitland Labs to establish drug development facility
Spotlight Innovation has finalized plans for entering into an agreement with Maitland Labs, based in Orlando, Florida, to establish its drug production and product development facilities at Maitland Lab’s sterile fill drug production plant, currently under construction.
Drug Research > Drug Discovery & Development > News

PBR Supplier Recommendations

LABORATORIOS INIBSA - Pharmaceutical Contract Manufacturing Company
LABORATORIOS INIBSA is a pharmaceutical contract manufacturing company. We have more than 60 years' experience and belong to the INIBSA GROUP. INIBISA supplies products and services to Biotools, Inibsa Dental and Inibsa Hospital, as well as other pharmaceutical companies through our contract manufacturing division. From our facilities in Lliçà de Vall, 20km from Barcelona LABORATORIOS INIBSA currently supplies more than 50 countries worldwide.... Drug Research > Drug Discovery & Development > Suppliers
Chemoswed - Suppliers of Active Pharmaceutical Ingredients
Chemoswed is the reliable Swedish custom synthesis specialist, supplying active ingredients since 1944. With a background in Pharmacia, Chemoswed is since 1996 an independent entity within the DuPont group, offering cost-effective, turn-key solutions to API needs worldwide.We have established unparalleled experience and technology, enabling efficient development and production of quality active pharmaceutical ingredients in quantities from 100 grams to 50 tons.... Drug Research > Drug Discovery & Development > Suppliers
Novo Nordisk Pharmatech A/S - Insulin Human and Benzalkonium Chloride Products
Novo Nordisk Pharmatech A/S is a Novo Nordisk company that specialises in the supply of ingredients for the biopharmaceutical and pharmaceutical industries, such as insulin human for cell culture media and cGMP manufactured quaternary ammonium compounds (usually referred to as quats) such as benzalkonium chloride, cetrimide and cetrimonium bromide.... Drug Research > Drug Discovery & Development > Suppliers
Biovian - cGMP Contract Manufacturing of Biopharmaceuticals
Biovian is a dynamic and effective new generation one-stop-shop CMO in cGMP contract manufacturing of biopharmaceuticals. Biovian's services cover the full range from antigen isolation, expression, vector construction, cell line cultivation, cGMP protein purification to product fill and finish.... Drug Research > Drug Discovery & Development > Suppliers
Tosoh Bioscience - Your Specialist in Separation
Tosoh Bioscience is an acknowledged global leader in the field of liquid chromatography with a strong focus on bioseparations. We offer solutions for research, drug discovery, clinical chemistry, environmental analysis, manufacturing and other industrial applications. ... Drug Research > Drug Discovery & Development > Suppliers
See more

PBR White Paper Recommendations

1.5 Specific dsDNA Quantification UV/VIS-based cDrop™ Method vs Picogreen® Fluorescent Assay By Trinean
Precise quantification and normalization of isolated genomic DNA is critical for advanced molecular testing in life science research and molecular diagnostics. UV-Vis based quantification has long been the method of choice, mainly because of its convenience. However, determining the DNA concentration based on the absorbance at 260nm suffers from interference of components such as RNA, proteins and phenols. Alternative methods, such as the PicoGreen® based Quant-iT™ assay, based on fluorescence enhancement upon binding with dsDNA have been developed to address this issue.... Drug Research > Drug Discovery & Development > White Papers 1.3 Micro-volume Protein Quantification using the DropSense96 Droplet Plate Reader By Trinean
The measurement of protein concentration in aqueous samples is an important assay in biochemistry research and protein production facilities. Spectrophotometric protein quantification assays are commonly used methods to rapidly determine the concentration of a protein. They utilize the direct UV absorbance of the protein at 280nm in combination with its extinction coefficient or an indirect dye-based methods like BCA, Lowry and Bradford assays.... Drug Research > Drug Discovery & Development > White Papers 1.2 DropSense96 and its DropPlates, a Versatile Tool for Nucleic Acid and Protein Droplet Quantification By Trinean
As the demand for molecular tests increases, automated systems for biomolecule isolation and sample analysis are becoming popular. These facilitate integration of the complete molecular test in a full automatic set-up with liquid robots and bar-coded sample tracking resulting in a significant higher throughput while minimizing tedious manual repetitive tasks. The Trinean technology is a unique combination of the DropSense96 droplet plate reader, the 96well DropPlate microfuidic consumables and the DropQuant analytical software enabling direct quantification of small biomolecule samples in these high throughput, automated workflow.... Drug Research > Drug Discovery & Development > White Papers 1.14 Droplet UV/VIS Quantification of Native Proteins in Biopharmaceutical Processing By Trinean
Biopharmaceuticals are mainly produced by microbial fermentation or in animal cell cultures. As a consequence, a cascade of procedures including purification and characterization are required throughout the processing chain to obtain the protein at the desired level of purity and potency. Within these processes, quantification of the protein of interest is mandatory at critical steps to maintain confidence in the processing results and fidelity in the end product.... Drug Research > Drug Discovery & Development > White Papers 1.20 Quantification of His-tagged IgG antibodies after IMAC Ni-column purification By Trinean
Trinean introduces a new cDrop™ application suited for the quantification (OD280) of IgG antibodies and derivatives like Fab fragments during purification by IMAC Ni-columns using imidazole-containing buffers.... Drug Research > Drug Discovery & Development > White Papers See more
1-15 of 5264 results